Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 sites80 target enrollmentJanuary 1, 2005

ConditionsPatients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment: 80
Primary Endpoint: Use of radiomics
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.

The study aims to apply radiomics for the prediction of response to neoadjuvant therapy.

Registry

clinicaltrials.gov

Start Date

January 1, 2005

End Date

November 15, 2022

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Responsible Party

Principal Investigator

Agnes Annamaria

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Eligibility Criteria

Inclusion Criteria

•Patients with locally advanced stomach cancer undergoing neoadjuvant chemotherapy and gastrectomy between January 2005 and August 2022

Exclusion Criteria

•Siewert 1 tumors;
•Patients who have received neoadjuvant with the addition of a biological drug;
•Patients who have received radiotherapy;
•Patients without staging CT scan or with insufficient image quality in terms of phases performed, pixel spacing, slide thickness (mandatorily: \> 5 mm) or artefacts.